Video

Dr. Sippel on the Importance of the Initial Surgery for MTC

Rebecca S. Sippel, MD, from the University of Wisconsin, discusses the importance of the initial surgery for patients with medullary thyroid cancer on outcomes.

Rebecca S. Sippel, MD, associate professor of surgery, University of Wisconsin, Madison, Wisconsin, discusses the importance of the initial surgical procedure for the management of patients with medullary thyroid cancer (MTC).

The initial surgery for MTC substantially dictates and impacts the long-term prognosis for patients. The most adequate and successful surgery requires proper preoperative diagnosis and planning, Sippel believes. Following a diagnosis by fine-needle aspiration cytology, an appropriate staging evaluation using calcitonin levels and a neck ultrasound establishes whether the disease is regional or metastatic and helps determine the extent of the surgery.

Sippel recommends a total thyroidectomy plus a comprehensive bilateral central neck dissection (CND) for every patient with MTC, at the first surgical intervention. She warns that a bilateral CND is difficult to perform in a second procedure, warranting the upfront use in every patient since nodal disease is common. However, in some cases, a lateral or ipsilateral lateral neck dissection may also be effective, she adds.

Unlike other types of thyroid cancer, surgical management is the mainstay for MTC and must be aggressive and comprehensive at the initial operation in order to achieve the best results.

<<<

View coverage from the 2012 ATA Annual Meeting

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center